Company Overview and News

16
VistaGen: Expensive At 12x Its Book Value Per Share

2018-10-09 seekingalpha - 5
VistaGen is a clinical-stage biopharmaceutical company developing treatments to fight depression and other central nervous system illnesses.
BHVN CERC AXSM VTGN

 
CERC / Cerecor Inc. 424B3 (Prospectus)

2018-10-05 sec.gov
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration no. 3
CERC

 
CERC / Cerecor Inc. S-3/A

2018-10-02 sec.gov
Table of Contents As filed with the Securities and Exchange Commission on October 2, 2018
CERC

1
CERC / Cerecor Inc. / ARMISTICE CAPITAL, LLC - null (Activist Investment)

2018-09-27 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
CERC

1
CERC / Cerecor Inc. / ARMISTICE CAPITAL, LLC - null (Activist Investment)

2018-09-27 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
CERC

1
CERC / Cerecor Inc. 8-K (Current Report)

2018-09-27 sec.gov - 1
UNITED STATES
CERC

 
CERC / Cerecor Inc. 424B3 (Prospectus)

2018-09-26 sec.gov
Filed Pursuant to Rule 424(b)(3) Registration No. 333-204905
CERC

2
CERC / Cerecor Inc. 8-K (Current Report)

2018-09-26 sec.gov - 2
UNITED STATES
CERC

 
Cerecor to Participate in Upcoming Healthcare Conferences

2018-09-26 globenewswire
BALTIMORE, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today announced that the Company’s management will attend and host investor meetings at the upcoming Oppenheimer Fall Summit focused on Specialty Pharma and Rare Diseases on Thursday, September 27, 2018 at the Langham Hotel in New York.
CERC CERCZ CERCW

 
Cerecor to Acquire Ichorion Therapeutics

2018-09-25 globenewswire
Transaction worth approximately $26.6 Million in Stock Plus Potential Milestones Accelerates Cerecor’s Transformation Strategy; Strengthens Rare Disease Pipeline and Expands Pediatric Portfolio
CERC CERCZ CERCW

 
CERC / Cerecor Inc. null

2018-09-21 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,Q M-34O3R Q,2]%(#(X,37!E+UA2968O5ULQ(#(@,5T^/G-T
CERC

 
CERC / Cerecor Inc. null

2018-09-21 sec.gov
CERC

 
CERC / Cerecor Inc. null

2018-09-21 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]4>7!E+UA/8FIE8W0O0V]L;W)3 M<&%C92]$979I8V5'
CERC

CERC : Cerecor Stock Analysis and Research Report

2017-11-04 - Asif

Cerecor is a biopharmaceutical company that is developing innovative drug candidates to make a difference in the lives of patients with neurologic and psychiatric disorders. The company's lead drug candidate is CERC-301, which the company currently intend to explore as a novel treatment for orphan neurologic indications. The company also have two pre-clinical stage compounds, CERC-611 and CERC-406. The company's portfolio of product candidates is summarized below: CERC-301: Orphan Neurologic Diseases. CERC‑301 belongs to a class of compounds known as antagonists of the N‑methyl‑D‑aspartate, or NMDA, receptor, a receptor subtype of the glutamate neurotransmitter system that is responsible for controlling neurologic adaptation. The company believe CERC‑301 specifically blocks the NMDA receptor subunit 2B, or NR2B. Cerecor has conducted two Phase 2 studies with this drug candidate as a potential adjunctive treatment for major depressive disorders, or MDD, in which the company obs...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 15671L109